



Botulinum Toxin (Medical Policy II-16) Commercial Pre-Authorization (PA) Request Form

Please review the medical policy review criteria on providers.bluecrossmn.com prior to submission.

Effective May 1, 2019, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) providers are required to use the Availity® Provider Portal to submit preservice prior authorization requests. **Faxes and phone calls for these requests will no longer be accepted by Blue Cross.** Please complete the clinical sections on this form and attach it to your request at Availity.com to ensure a timely review.

Providers outside of Minnesota without electronic access can fax this form, along with clinical records to support the request, to (651) 662-2810.

Patient Information	<input type="checkbox"/> Request for Urgent Review: By checking this box, I certify that applying the standard review time may seriously jeopardize the life or health of the member or the member's ability to regain maximum function per Federal definition of "Urgent".		
	Member ID: _____ Group number: _____ Member name: _____ Date of birth (mm/dd/yy): _____ Member address: _____ Member city/state/zip: _____ Member phone: ____ - ____ - _____		
Servicing Provider Information	Contact person: _____ Phone: ____ - ____ - _____ Servicing provider name: _____ Servicing provider ID/NPI number: _____ Servicing provider address: _____ City/state/zip: _____ Servicing provider phone: ____ - ____ - _____ Servicing provider fax: ____ - ____ - _____ Inpatient/Outpatient Facility name: _____ Facility ID: _____		
Ordering Provider Info	Ordering provider name: _____ Ordering provider ID/NPI number: _____ Ordering provider address: _____ City/state/zip: _____ Ordering provider phone: ____ - ____ - _____ Ordering provider fax: ____ - ____ - _____		
Services/Procedures/Items Requested	Please attach all relevant clinical documentation that supports information selected in the form. Checking the boxes without submitting clinical documentation that supports the selection, may result in a denial of the PA request. Note: Requested Dose/Frequency AND Initial OR Renewal Sections must be completed.		
	HCPC/CPT Procedure Code(s)	ICD-10 Diagnosis Code(s)	Drug Administration

Member ID: _____

Botulinum Toxin Pre-Authorization Request Form

			Is Ordering or Servicing Provider above administering the drug? <input type="checkbox"/> Yes <input type="checkbox"/> No → If no, who will be administering the drug? _____ → Is administering provider doing Buy and Bill? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Services/Procedures/ Items Requested	Please select the requested medication(s) and answer the corresponding questions.				
	<input type="checkbox"/> Botox	Requested Dose/Frequency	Start Date (mm/dd/yy)	End Date (mm/dd/yy)	
		Is maximum cumulative dose \leq 400 units every 12 weeks?		<input type="checkbox"/> Yes <input type="checkbox"/> No*	
		Is patient hypersensitive to any component of the Botox formulation?		<input type="checkbox"/> Yes <input type="checkbox"/> No*	
		Does patient have an infection at the injection site?		<input type="checkbox"/> Yes <input type="checkbox"/> No	
	Does patient have a urinary tract infection or urinary retention?		<input type="checkbox"/> Yes <input type="checkbox"/> No		
	<input type="checkbox"/> Dysport	Requested Dose/Frequency	Start Date (mm/dd/yy)	End Date (mm/dd/yy)	
		What is the patient's current weight? _____ <input type="checkbox"/> KG <input type="checkbox"/> LB			
		Is maximum cumulative dose \leq 1,000 units every 12 weeks?		<input type="checkbox"/> Yes <input type="checkbox"/> No*	
		Is patient hypersensitive to any component of the Dysport formulation?		<input type="checkbox"/> Yes <input type="checkbox"/> No*	
		Does patient have an allergy to cow's milk protein?		<input type="checkbox"/> Yes <input type="checkbox"/> No	
		Does patient have an infection at the injection site?		<input type="checkbox"/> Yes <input type="checkbox"/> No	
<input type="checkbox"/> Myobloc	Requested Dose/Frequency	Start Date (mm/dd/yy)	End Date (mm/dd/yy)		
	Is maximum cumulative dose \leq 10,000 units every 12 weeks?		<input type="checkbox"/> Yes <input type="checkbox"/> No*		
	Is patient hypersensitive to any component of the Myobloc formulation?		<input type="checkbox"/> Yes <input type="checkbox"/> No*		
	Does the patient have an infection at the injection site?		<input type="checkbox"/> Yes <input type="checkbox"/> No		
<input type="checkbox"/> Xeomin	Requested Dose/Frequency	Start Date (mm/dd/yy)	End Date (mm/dd/yy)		
	Is maximum cumulative dose \leq 400 units every 12 weeks?		<input type="checkbox"/> Yes <input type="checkbox"/> No*		
	Is patient hypersensitive to any component of the Xeomin formulation?		<input type="checkbox"/> Yes <input type="checkbox"/> No*		
	Does the patient have an infection at the injection site?		<input type="checkbox"/> Yes <input type="checkbox"/> No		

	<p>Is the requested dose above the maximum treatment dose specified in the medical policy for the indication? <input type="checkbox"/> Yes* <input type="checkbox"/> No</p> <p>If yes, has the patient's dose been titrated up based on ineffective symptom control at lower doses? <input type="checkbox"/> Yes* <input type="checkbox"/> No</p> <p>Is the requested dosing interval more frequent than the minimum dosing interval specified in the medical policy for the indication? <input type="checkbox"/> Yes* <input type="checkbox"/> No</p> <p>If yes, has the patient's dosing interval been shortened based on ineffective symptom control at longer intervals? <input type="checkbox"/> Yes* <input type="checkbox"/> No</p> <p>*Please attach all relevant clinical documentation supporting dosing and frequency request</p>
Initial Request	<p align="center">Please select the indication(s) and answer the corresponding questions. If applicable, please attach supporting documentation for drug intolerance, contraindications or hypersensitivity</p>
	<p><input type="checkbox"/> Blepharospasm associated with dystonia, including benign essential blepharospasm or VII (facial) nerve disorders</p> <p>If requesting Botox or Dysport, is the patient 12 years of age or older? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If requesting Xeomin, is the patient 18 years of age or older? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
	<p><input type="checkbox"/> Cervical dystonia (spasmodic torticollis; applicable whether congenital, due to child birth injury or traumatic injury)</p> <p>Does the patient have a sustained head tilt or abnormal posturing with a limited range of motion in the neck? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have a history of recurrent involuntary contraction of one or more of the muscles of the neck (e.g., sternoicleidomastoid, splenius, trapezius, or posterior cervical muscles)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
	<p><input type="checkbox"/> Chronic anal fissure</p> <p>Has the patient tried any conventional therapy (e.g., bulking agents, sitz baths, laxatives, dietary changes, or 0.4% intra-anal nitroglycerin)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
	<p><input type="checkbox"/> Chronic migraine headache</p> <p>Note: Please provide documentation of clinical evaluation and intolerance to the prerequisite therapy.</p> <p>Is the patient 18 years of age or older? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient had 15 or more headache days (headaches that last 4 hours or more per day) per month for 3 months or longer, with 50% or more of headaches being migraine/probable migraine? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient been evaluated for and confirmed not to have medication overuse headache? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient tried ONE conventional agent prerequisite from at least TWO different classes? (check all that apply) <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <ul style="list-style-type: none"> <input type="checkbox"/> Antidepressants (e.g., amitriptyline, venlafaxine) <input type="checkbox"/> Antiepileptics (e.g., topiramate, valproic acid) <input type="checkbox"/> Calcitonin gene-related peptides (CGRPs) (e.g., erenumab, fremanezumab, galcanezumab) <input type="checkbox"/> Calcium channel or beta blockers (e.g., propranolol, metoprolol, bisoprolol, verapamil) <input type="checkbox"/> Other: _____

Initial Request	<input type="checkbox"/> Dystonia associated with ONE of the following conditions: <input type="checkbox"/> Focal upper limb dystonia (e.g., organic writer’s cramp) <input type="checkbox"/> Oromandibular dystonia (e.g., orofacial dyskinesia, jaw-closing dystonia, Meige syndrome) <input type="checkbox"/> Laryngeal dystonia (adductor spasmodic dysphonia) <input type="checkbox"/> Idiopathic (primary or genetic) torsion dystonia <input type="checkbox"/> Symptomatic (acquired) torsion dystonia								
	<input type="checkbox"/> Esophageal achalasia Has the patient tried and not responded to pneumatic dilation or myotomy? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient a candidate for pneumatic dilation of myotomy? <input type="checkbox"/> Yes <input type="checkbox"/> No								
	<input type="checkbox"/> Facial synkinesis								
	<input type="checkbox"/> Hemifacial spasm								
Initial Request	<input type="checkbox"/> Overactive bladder Does the patient have symptoms of urge urinary incontinence, urgency, and frequency? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient had inadequate response to conservative therapies, including bladder training, pelvic floor muscle exercises, and fluid management? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient tried at least TWO first-line conventional agent prerequisites from TWO different classes? (Check all that apply.) <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Anticholinergic agent (e.g., oxybutynin, tolterodine, trospium, darifenacin, solifenacin, or fesoterodine) <input type="checkbox"/> Myrbetriq (mirabegron) <input type="checkbox"/> Other: _____ Does the patient have a documented intolerance, FDA-labeled contraindication, or hypersensitivity to any of the first-line conventional agent prerequisites? <input type="checkbox"/> Yes <input type="checkbox"/> No (Check all that apply.) <input type="checkbox"/> Anticholinergic agent (e.g., oxybutynin, tolterodine, trospium, darifenacin, solifenacin, or fesoterodine) <input type="checkbox"/> Myrbetriq (mirabegron) <input type="checkbox"/> Other: _____								
	<input type="checkbox"/> Palmar or axillary hyperhidrosis Has the patient tried 20% aluminum chloride solution? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have a documented intolerance, FDA-labeled contraindications, or hyper-sensitivity to 20% aluminum chloride solution? <input type="checkbox"/> Yes <input type="checkbox"/> No								
	<input type="checkbox"/> Sialorrhea Has the patient tried any conventional agent prerequisites (e.g., oral hyoscine, atropine drops, glycopyrrolate, or amitriptyline)? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have a documented intolerance, FDA-labeled contraindication, or hyper-sensitivity to any of the conventional agent prerequisites? <input type="checkbox"/> Yes <input type="checkbox"/> No								
	<input type="checkbox"/> Spasticity associated with ONE of the following conditions: <table style="width: 100%; border: none;"> <tr> <td><input type="checkbox"/> Cerebral Palsy</td> <td><input type="checkbox"/> Spastic hemiplegia</td> </tr> <tr> <td><input type="checkbox"/> Stroke</td> <td><input type="checkbox"/> Neuromyelitis optica</td> </tr> <tr> <td><input type="checkbox"/> Acquired spinal cord or traumatic brain injury</td> <td><input type="checkbox"/> Multiple sclerosis</td> </tr> <tr> <td><input type="checkbox"/> Hereditary spastic paraplegia</td> <td><input type="checkbox"/> Schilder’s disease</td> </tr> </table>	<input type="checkbox"/> Cerebral Palsy	<input type="checkbox"/> Spastic hemiplegia	<input type="checkbox"/> Stroke	<input type="checkbox"/> Neuromyelitis optica	<input type="checkbox"/> Acquired spinal cord or traumatic brain injury	<input type="checkbox"/> Multiple sclerosis	<input type="checkbox"/> Hereditary spastic paraplegia	<input type="checkbox"/> Schilder’s disease
	<input type="checkbox"/> Cerebral Palsy	<input type="checkbox"/> Spastic hemiplegia							
<input type="checkbox"/> Stroke	<input type="checkbox"/> Neuromyelitis optica								
<input type="checkbox"/> Acquired spinal cord or traumatic brain injury	<input type="checkbox"/> Multiple sclerosis								
<input type="checkbox"/> Hereditary spastic paraplegia	<input type="checkbox"/> Schilder’s disease								
<input type="checkbox"/> Spasticity of the lower limb									

		<input type="checkbox"/> Spasticity of the upper limb		
		<input type="checkbox"/> Strabismus, including persistent cranial VI nerve palsy of one month or longer Has the patient had inadequate response to corrective lenses? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient had inadequate response to any other additional corrective therapies? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have good vision in both eyes? <input type="checkbox"/> Yes <input type="checkbox"/> No Are the patient's eye movements restricted? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have a small-to-moderate angle of esotropia? <input type="checkbox"/> Yes <input type="checkbox"/> No Is it possible for the patient to experience binocular vision? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Initial Request		<input type="checkbox"/> Urinary incontinence due to detrusor overactivity associated with a neurologic conditions (e.g., spinal-cord injury, multiple sclerosis) Has the patient tried at least TWO first-line conventional agent prerequisites from TWO different classes? (check all that apply) <input type="checkbox"/> Yes <input type="checkbox"/> No <div style="margin-left: 20px;"> <input type="checkbox"/> Anticholinergic agent (e.g., oxybutynin, tolterodine, trospium, darifenacin, solifenancin, or fesoterodine) <input type="checkbox"/> Myrbetriq (mirabegron) <input type="checkbox"/> Other: _____ </div> Does the patient have a documented intolerance, FDA-labeled contraindication, or hypersensitivity to any of the first-line conventional agent prerequisites? (check all that apply) <input type="checkbox"/> Yes <input type="checkbox"/> No <div style="margin-left: 20px;"> <input type="checkbox"/> Anticholinergic agent (e.g., oxybutynin, tolterodine, trospium, darifenacine, solifenacine, or fesoterodine) <input type="checkbox"/> Mybetriq (mirabegron) <input type="checkbox"/> Other: _____ </div>		
		<input type="checkbox"/> Other (please specify below) <div style="border: 1px solid black; height: 80px; margin-top: 5px;"></div>		
		Please provide supporting documentation for the requested medication		
Renewal Request		Note: Requested Dose/Frequency AND Patient History Sections must also be completed.		
		Has the patient been previously approved for the requested agent through Blue Cross and Blue Shield of Minnesota's initial review process? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have an approved diagnosis listed under "Initial Request"? <input type="checkbox"/> Yes <input type="checkbox"/> No		
		If the diagnosis is chronic migraine headache: Has treatment with the requested agent reduced the number of headache days by at least 7 days per month from baseline prior to therapy)?* <input type="checkbox"/> Yes <input type="checkbox"/> No		
		If the diagnosis is NOT chronic migraine headache: Has treatment with the requested agent resulted in a reduction of symptom severity and/or frequency from baseline (prior to therapy)?* <input type="checkbox"/> Yes <input type="checkbox"/> No		
	*Please provide supporting documentation.			

Please attach all relevant clinical documentation that supports information selected in the form.

Member ID: _____

Botulinum Toxin Pre-Authorization Request Form

Page | 6

Description / Additional Information:

Total pages: _____